Eye Color Genes Linked to Uveal Melanoma Risk
Scientists from the Ohio State University (The James) Comprehensive Cancer Center and Perlmutter Cancer Center of NYU School of Medicine have found an association between genes linked to eye color and development of uveal melanoma.
Transforming Melanoma Into a Nonthreatening Illness
A new study is suggesting that it may be possible to turn melanoma into a nonthreatening, easily curable disease.
Right Arm Skin Lesion Found in 47-Year-Old Man
A 47-year-old man presents with an “atrophic” lesion of the skin in the right arm. After a biopsy is performed, what is your diagnosis?
On-treatment Biomarkers Predict Immune Checkpoint Blockade Responses in Melanoma
Immune response markers from on-treatment—but not pretreatment—melanoma biopsies predict responses to immune checkpoint blockade.
Adding Localized Therapy to Ipilimumab Boosts Survival in Melanoma
Patients with metastatic melanoma may benefit from the addition of a local tumor-targeted treatment in addition to ipilimumab.
Shorter Turnaround Time for BRAF Mutation Testing
Obtaining blood biopsies instead of invasive tissue biopsies may be less risky for patients, faster, and cost less.
Driver Mutations, Tumor Diameter Prognostic in Tumors of the Eye
Along with gene expression signatures from a 15-loci panel, tumor diameter and specific driver mutations predict metastasis risk and survival among patients with uveal melanoma.
Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma
In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
Rheumatic Adverse Events Reported for Patients Treated with Nivolumab, Ipilimumab
Inflammatory arthritis and sicca syndrome appear to be immune-related adverse events among some patients undergoing cancer treatment with the immune checkpoint inhibitors nivolumab and ipilimumab.
Trametinib May Play a Dual Role in Merkel Cell Carcinoma
Trametinib, which is approved by the FDA for melanoma and other cancers, may block viral infection by stopping Merkel cell polyomavirus transcription and replication.